City of Hope Southwest Oncology Group Clinical Trials

本提案的总体目标是支持希望之城国家医疗中心的参与。 西南肿瘤学小组（SWOG）研究性临床试验中心（COH）。COH，一个 NCI指定的综合癌症中心，为临床研究提供了强有力的领导 在过去的六年里，SWOG的活动。COH的SWOG成员提供了大量的科学数据， 为恶性血液病的新治疗方案的开发以及所有方面提供投入 高剂量化疗与干细胞支持组;此外，在肿瘤学的专业知识 药理学、细胞遗传学、免疫治疗、泌尿生殖系统癌症、妇科病理学和肿瘤 生物学将继续支持SWOG的试验方案开发，并参与整个集团的工作。 II期和III期研究。来自COH的SWOG成员也为研究活动做出了重大贡献 在肿瘤手术和癌症预防方面。COH医生和科学家提高了他们的领导能力 在当前的供资周期内，在SWOG范围内开展活动，增加了生殖泌尿系统的主席职位， 委员会的睾丸癌小组委员会和新成立的早期治疗委员会继续 担任骨髓和干细胞移植委员会主席，以及妇科 病理学和肿瘤生物学小组委员会。除了这些领导职位外， SWOG内COH研究人员的科学生产力继续提高。上一次的 对COH参与SWOG的竞争性审查，9名COH研究者发表了18篇论文， 报告SWOG临床研究的摘要;在过去的六年中，12名COH研究者 发表了31篇论文和28篇摘要，在高质量的同行评审出版物中描述了SWOG研究。 基于一个专门的，多学科的医生团队在病理学，肿瘤外科， 放射肿瘤学、癌症控制以及内科肿瘤学、实验治疗学和 致力于SWOG所追求的研究的血液学专家， 预计COH将在未来的资金投入中继续增加SWOG临床试验的患者人数 周期此外，由COH参与SWOG设计的创新治疗概念将 扩大大南加州地区的研究性癌症治疗的可用性。

The overall objective of this proposal is to support the participation of the City of Hope National Medical Center (COH) in the investigational clinical trials of the Southwest Oncology Group (SWOG). The COH, an NCI-designated Comprehensive Cancer Center, has supplied strong leadership for the clinical research activities of SWOG during the past six years. SWOG members at COH have provided substantial scientific input into the development of new therapeutic programs for hematological malignancies as well as all aspects of high-dose chemotherapy with stem cell support for the group; in addition, expertise in oncologic pharmacology, cytogenetics, immunotherapy, genitourinary cancers, and gynecologic pathology and tumor biology will continue to support pilot protocol development for SWOG as well as participation in group-wide phase II and phase III studies. SWOG members from COH also contribute substantially to research activities in oncologic surgery and cancer prevention. COH physicians and scientists have increased their leadership activities within SWOG during the current funding cycle, adding the chairmanships of the Genitourinary Committee's Testis Cancer Subcommittee and the newly formed Early Therapeutics Committee to continuing service as chairs of the Bone Marrow and Stem Cell Transplantation Committee, and the Gynecology Committee's Pathology and Tumor Biology Subcommittees. In addition to these leadership positions, the scientific productivity of COH investigators within SWOG has continued to increase. At the time of the last competitive review of COH's participation in SWOG, 9 COH investigators had published 18 papers and 14 abstracts reporting SWOG clinical investigations; over the past six years, 12 COH investigators have published 31 papers and 28 abstracts describing SWOG research in high-quality, peer-reviewed publications. Based on the presence of a dedicated, multidisciplinary team of physicians in Pathology, Surgical Oncology, Radiation Oncology, and Cancer Control as well as Medical Oncology, Experimental Therapeutics, and Hematology who are committed to the investigations pursued by SWOG, substantive scientific leadership of and patient accrual to SWOG clinical trials by the COH can be predicted to continue over the coming funding cycle. Furthermore, participation by the COH in the innovative treatment concepts devised by SWOG will broaden the availability of investigational cancer care in the greater Southern California region.